| 1 | in 1988 as an | | | | | | | 2 | 0.86% |
| 2 | integrated private sector pharmaceutical | | | | | | | 2 | 0.86% |
| 3 | incorporated in 1988 as | | | | | | | 2 | 0.86% |
| 4 | authority guidelines and already | | | | | | | 1 | 0.43% |
| 5 | for oral solid dosage | | | | | | | 1 | 0.43% |
| 6 | oral solid dosage form | | | | | | | 1 | 0.43% |
| 7 | solid dosage form in | | | | | | | 1 | 0.43% |
| 8 | dosage form in compliance | | | | | | | 1 | 0.43% |
| 9 | form in compliance to | | | | | | | 1 | 0.43% |
| 10 | in compliance to latest | | | | | | | 1 | 0.43% |
| 11 | stringent regulatory authority guidelines | | | | | | | 1 | 0.43% |
| 12 | regulatory authority guidelines and | | | | | | | 1 | 0.43% |
| 13 | and already applied in | | | | | | | 1 | 0.43% |
| 14 | guidelines and already applied | | | | | | | 1 | 0.43% |
| 15 | already applied in sra | | | | | | | 1 | 0.43% |
| 16 | countries the path of | | | | | | | 1 | 0.43% |
| 17 | the path of success | | | | | | | 1 | 0.43% |
| 18 | path of success lies | | | | | | | 1 | 0.43% |
| 19 | of success lies in | | | | | | | 1 | 0.43% |
| 20 | success lies in its | | | | | | | 1 | 0.43% |
| 21 | lies in its belief | | | | | | | 1 | 0.43% |
| 22 | in its belief of | | | | | | | 1 | 0.43% |
| 23 | designed for oral solid | | | | | | | 1 | 0.43% |
| 24 | equipped with new ultramodern | | | | | | | 1 | 0.43% |
| 25 | facility designed for oral | | | | | | | 1 | 0.43% |
| 26 | acquired an unmatched record | | | | | | | 1 | 0.43% |
| 27 | 1988 as an integrated | | | | | | | 1 | 0.43% |
| 28 | as an integrated private | | | | | | | 1 | 0.43% |
| 29 | an integrated private sector | | | | | | | 1 | 0.43% |
| 30 | private sector pharmaceutical formulation | | | | | | | 1 | 0.43% |
| 31 | sector pharmaceutical formulation manufacturer | | | | | | | 1 | 0.43% |
| 32 | formulation manufacturer has acquired | | | | | | | 1 | 0.43% |
| 33 | manufacturer has acquired an | | | | | | | 1 | 0.43% |
| 34 | has acquired an unmatched | | | | | | | 1 | 0.43% |
| 35 | an unmatched record of | | | | | | | 1 | 0.43% |
| 36 | laboratories equipped with new | | | | | | | 1 | 0.43% |
| 37 | unmatched record of managing | | | | | | | 1 | 0.43% |
| 38 | niche product in formulations | | | | | | | 1 | 0.43% |
| 39 | product in formulations with | | | | | | | 1 | 0.43% |
| 40 | in formulations with who | | | | | | | 1 | 0.43% |